Udenafil - Dong-A ST/Mezzion

Drug Profile

Udenafil - Dong-A ST/Mezzion

Alternative Names: DA-8159; ME-3113; MZ101; Udzire; WC-3043; WC-3055; Zydena

Latest Information Update: 25 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Abdi Ibrahim Pharmaceuticals; Dong-A Pharmaceutical; Dong-A ST; Dr Falk Pharma; Meiji Seika Pharma; Mezzion; National Heart, Lung and Blood Institute; Seoul National University Hospital; Valenta; Zydus Urosciences
  • Class Antihypertensives; Erectile dysfunction therapies; Pyrazolones; Pyrimidinones; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital heart defects
  • New Molecular Entity Yes
  • Available For Licensing Yes - Benign prostatic hyperplasia; Erectile dysfunction; Portal hypertension; Pulmonary hypertension

Highest Development Phases

  • Marketed Erectile dysfunction
  • Phase III Congenital heart defects
  • Phase II/III Pulmonary arterial hypertension
  • Phase II Benign prostatic hyperplasia; Portal hypertension
  • Preclinical Overactive bladder
  • Discontinued Heart failure; Pulmonary hypertension

Most Recent Events

  • 22 Jun 2018 Mezzion Pharma completes enrolment in the phase III FUEL trial (In adolescents) for Congenital heart disorders in USA, Canada and South Korea
  • 23 Feb 2018 Preclinical trials in Overactive bladder in South Korea (PO) (Mezzion pipeline, February 2018)
  • 31 Jul 2017 Tabuk Pharmaceutical Manufacturing acquires marketing license for udenafil in Saudi Arabia, Bahrain, Iraq, Kuwait, Oman, Qatar and the United Arab Emirates
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top